Prostacyclin therapy is a mainstay of the management of pulmonary arterial hypertension (PAH). Inhaled prostacyclins present safe and effective options for the management of PAH that limit systemic side effects. We describe the first reported case of life‐threatening bronchospasm and acute respiratory failure associated with inhaled prostacyclin administration.
No takes yet. Share an insight, caveat, or question.
Steinbacher et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: